Stefan Laufer

发表

4-[3-(4-Fluorophenyl)quinoxalin-2-yl]-N-isopropylpyridin-2-amine

Pierre Koch, Dieter Schollmeyer, Stefan Laufer, 2009, Acta crystallographica. Section E, Structure reports online.

6-(4-Chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-carbaldehyde

Dieter Schollmeyer, Stefan Laufer, Peter R. W. E. F. Keck, 2011, Acta crystallographica. Section E, Structure reports online.

tert-Butyl N-benzyl-N-[4-(4-fluorobenzoylmethyl)-2-pyridyl]carbamate

Pierre Koch, Stefan Laufer, Dieter Schollmeyer, 2008, Acta crystallographica. Section E, Structure reports online.

11th German Conference on Chemoinformatics (GCC 2015)

Timothy Clark, Jonathan W. Essex, Peter Kolb, 2016, J. Cheminformatics.

N-(4-Chloropyridin-2-yl)-N-methoxymethyl-4-methylbenzenesulfonamide

Stefan Laufer, Dieter Schollmeyer, Stefanie Bühler, 2010, Acta crystallographica. Section E, Structure reports online.

Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome

Jürgen Bajorath, Stefan Laufer, Oliver Laufkötter, 2020, Data in brief.

2-(Bicyclo[2.2.1]hept-5-en-2-yl)-1H-pyrrolo[2,3-b]pyridine

Dieter Schollmeyer, Stefan Laufer, Roland Selig, 2010, Acta crystallographica. Section E, Structure reports online.

N-(4-Chloropyridin-2-yl)-N-(4-methylphenylsulfonyl)acetamide

Stefan Laufer, Dieter Schollmeyer, Stefanie Bühler, 2010, Acta crystallographica. Section E, Structure reports online.

tert-Butyl N-(4-methyl-2-pyridyl)carbamate

Pierre Koch, Stefan Laufer, Dieter Schollmeyer, 2008, Acta crystallographica. Section E, Structure reports online.

4-[4-(4-Fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-3-yl]-1-methylpyridinium iodide–4-[3-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydroisoxazol-4-yl]-1-methylpyridinium iodide (0.6/0.4)

Stefan Laufer, Dieter Schollmeyer, Simona Margutti, 2007, Acta crystallographica. Section E, Structure reports online.

tert-Butyl N-[(3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl]-N-methylcarbamate

Stefan Laufer, Michael Forster, Dieter Schollmeyer, 2013, Acta crystallographica. Section E, Structure reports online.

N-[(3RS,4SR)-1-Benzyl-4-methylpiperidin-3-yl]-1-(4-methylphenylsulfonyl)-5-nitro-1H-pyrrolo[2,3-b]pyridin-4-amine

Stefan Laufer, Dieter Schollmeyer, Ellen Pfaffenrot, 2012, Acta crystallographica. Section E, Structure reports online.

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-ylsulfanyl]butanoate

Pierre Koch, Stefan Laufer, Dieter Schollmeyer, 2008, Acta crystallographica. Section E, Structure reports online.

N-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-5-nitro-1-phenylsulfonyl-1H-pyrrolo[2,3-b]pyridine-4-amine

Stefan Laufer, Dieter Schollmeyer, Ellen Pfaffenrot, 2012, Acta crystallographica. Section E, Structure reports online.

4-[2-(4-Fluorophenyl)-1H-pyrrol-3-yl]pyridine

Pierre Koch, Dieter Schollmeyer, Stefan Laufer, 2009, Acta crystallographica. Section E, Structure reports online.

1,4-Dimethyl-2-phenyl-6,7-dihydro-1H-pyrazolo[4,3-b]pyridine-3,5(2H,4H)-dione

Dieter Schollmeyer, Stefan Laufer, Marc Weisser, 2011, Acta crystallographica. Section E, Structure reports online.

1-[(3RS,4RS)-1-Benzyl-4-methylpiperidin-3-yl]-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine hemihydrate

Stefan Laufer, Dieter Schollmeyer, Ellen Pfaffenrot, 2012, Acta crystallographica. Section E, Structure reports online.

New frontiers in kinases: second generation inhibitors.

Jürgen Bajorath, Stefan Laufer, J. Bajorath, 2014, Journal of medicinal chemistry.

The Gastrointestinal Tolerability of the LOX/COX Inhibitor, Licofelone, is Similar to Placebo and Superior to Naproxen Therapy in Healthy Volunteers: Results From a Randomized, Controlled Trial

Stefan Laufer, Anton Buchner, S. Laufer, 2004, American Journal of Gastroenterology.

Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling

Stefan Laufer, Tanja Fehm, Hans Neubauer, 2007, BMC Biochemistry.

Assessing the target differentiation potential of imidazole-based protein kinase inhibitors.

Jürgen Bajorath, Stefan Laufer, Preeti Iyer, 2012, Journal of medicinal chemistry.

Achiral-chiral LC/LC-MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism.

Stefan Laufer, Bernd Kammerer, S. Laufer, 2005, Analytical biochemistry.

Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine.

Stefan Laufer, Daniel Rauh, Daniel Dauch, 2017, Angewandte Chemie.

Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.

Stefan Laufer, Dieter Schollmeyer, Christian Peifer, 2008, Journal of medicinal chemistry.

Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection

Andreas Zell, Stefan Laufer, Hans Neubauer, 2009, BMC Cancer.